Comparing Peginterferon Alfa-2a vs Ropeginterferon Alfa-2b
| Peginterferon alfa-2a | Ropeginterferon alfa-2b |
|
|---|
| Peginterferon alfa-2a | Ropeginterferon alfa-2b |
|
|---|---|---|
|
Prescription only
Prescribed for Hepatitis B, Polycythemia Vera, Thrombocythemia, Hepatitis C. Peginterferon alfa-2a may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Polycythemia Vera. Ropeginterferon alfa-2b may also be used for purposes not listed in this medication guide. |
Related suggestions Polycythemia Vera
|
| More about Peginterferon alfa-2a | More about Ropeginterferon alfa-2b | |
| Ratings & Reviews | ||
|
Peginterferon alfa-2a has an average rating of 7.3 out of 10 from a total of 19 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 16% reported a negative effect. |
Ropeginterferon alfa-2b has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
|
View all Peginterferon alfa-2a side effects |
View all Ropeginterferon alfa-2b side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Pegasys | Besremi | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
140 hours |
240 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 232 drugs are known to interact with Peginterferon alfa-2a:
|
A total of 452 drugs are known to interact with Ropeginterferon alfa-2b:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
N/A |
N/A |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
|
N/A |
||
| Related Treatment Guide | ||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vemlidy
Vemlidy (tenofovir alafenamide) is an oral, once-daily, antiviral tablet that may be used to treat ...
Baraclude
Baraclude (entecavir) is and antiviral medicine used to treat chronic hepatitis B. Includes ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Pegasys
Pegasys is used to treat chronic hepatitis B or C. Learn about side effects, interactions and ...
Epivir
Epivir (lamivudine) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Interferon alfa-2b
Interferon alfa-2b is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated ...
Lamivudine
Lamivudine is used for hepatitis b, HIV Infection, nonoccupational exposure, occupational exposure
Tenofovir disoproxil
Tenofovir disoproxil is used for hepatitis b, HIV Infection, nonoccupational exposure, occupational ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.